#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Prostate cancer Obesity Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Malignant melanoma Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Amyotrophic lateral sclerosis gene carrier Exudative retinopathy Cardiac sarcoidosis Myeloid leukaemia Primary amyloidosis Hidradenitis Fusarium infection Encephalitis autoimmune Thromboangiitis obliterans Oesophageal squamous cell carcinoma stage II Dupuytren's contracture Transitional cell carcinoma Peritoneal neoplasm Osteochondrodysplasia More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Basic Information Nephroblastoma – Diagnostics Prader-Willi syndrome – Treatment Mucopolysaccharidosis Sarcoma – Life with Disease Ewing’s sarcoma metastatic – Life with Disease Hereditary neuropathic amyloidosis – Life with Disease Primary biliary cholangitis – Basic Information Synovial sarcoma recurrent – Life with Disease Activated PI3 kinase delta syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Talquetamab Tamoxifen Clobetasol Glepaglutide Cefuroxime Human Serum Albumin 5% Anb032 Carbetocin Omeprazole Bexotegrast Mosaic Hbcoreag Amsacrine Polatuzumab Vedotin ULTEVURSEN CICLOPIROX Tetracaine Hydrochloride Mepacrine Regn7257 YOHIMBINE HYDROCHLORIDE Amb-05X More therapies…

    Learn about Your Condition

    Oesophageal atresia Marfan's syndrome Hepatitis D Colon cancer stage IV Chorioretinitis Immune-mediated renal disorder Lymphangioleiomyomatosis Trisomy 21 Ophthalmoplegia Haemorrhage Short-bowel syndrome Metastatic gastric cancer Progressive multiple sclerosis Skin papilloma Medulloblastoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Iceland

  • Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study on Rituximab, Lenalidomide, and Tafasitamab for Treating High-Risk and Low-Risk Follicular Lymphoma Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Lenalidomide
    • Rituximab
    • Tafasitamab
    Denmark Finland Iceland Norway Sweden

  • Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Nadroparin Calcium
    • Human Albumin Solution
    • Tinzaparin Sodium
    Denmark Finland Iceland The Netherlands Sweden

  • Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Mitomycin
    Denmark Iceland Norway Sweden

  • Study on the Safety and Effectiveness of Terbinafine Solution for Treating Mild to Moderate Nail Fungus in Children Aged 6-17 Years

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Terbinafine
    • Terbinafine Hydrochloride
    Denmark Iceland Italy Poland

  • Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Aficamten
    Czechia Denmark France Germany Greece Hungary +6
1 2 3 … 5
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Acetylcysteine Amide Aficamten Cytarabine Lenalidomide Dexamethasone Pelacarsen Methotrexate Prednisolone Sodium Succinate Methylprednisolone Sodium Succinate Methotrexate Sodium Quizartinib Dihydrochloride Mitomycin SAROGLITAZAR HEMIMAGNESIUM Doxorubicin Betamethasone Sodium Phosphate Durvalumab Carfilzomib Ticagrelor Rosuvastatin MAGNESIUM CARBONATE HEAVY Certolizumab Pegol Dexrazoxane Acetylsalicylic Acid Atorvastatin Calcium Carbonate Hydroxychloroquine Sulfate Mitoxantrone Hydrocortisone Sodium Phosphate Inclisiran Esomeprazole Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Acute lymphocytic leukaemia Acute myeloid leukaemia Arteriosclerosis Atrial fibrillation Bladder transitional cell carcinoma Breast cancer Cerebral amyloid angiopathy Chronic kidney disease Coronary artery disease Dyslipidaemia Dyspepsia End stage renal disease Follicular lymphoma Hypertrophic cardiomyopathy Infertility Intensive care Non-small cell lung cancer Plasma cell myeloma Primary biliary cholangitis Rheumatoid arthritis Small cell lung cancer extensive stage Transitional cell carcinoma

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!